GSK's silence sets tongues wagging

GlaxoSmithKline CEO Andrew Witty said two things yesterday that analysts are still parsing today. One: "There is no way we will be distracted by large-scale M&A going on in the sector--that's not for GlaxoSmithKline. Nothing that has happened in the past month has changed my view. You will see us make acquisitions but they will be small to medium-size and will not be a mega-merger."

Two: No 2009 sales forecast, no 2009 earnings guidance.

In both instances, Witty personified a headline in The Telegraph: "GlaxoSmithKline boss outlines go-it-alone policy." The company plans to forge ahead without hooking up with a big rival. And no other drugmaker is likely to have the guts--or foolishness, depending upon the point of view--to forego financial predictions for the coming year.

The Financial Times takes the long view. Short-term financial indicators are of limited use in the drugs business, because R&D is such a long, drawn-out process. Opening up to analysts about strategic objectives and benchmarks--that's more revelatory, it says, citing Witty's argument. But the paper also thinks there's a bit of "short-term pragmatism" in the move, because GSK's peers saw their shares drop when they issued less-than-encouraging forecasts. And other market-watchers figure the "no forecast" policy won't last long because the predictions have become such a fixture on the financial landscape.

Meanwhile, some analysts upgraded Glaxo stock on the strength of its cost-cutting plans--and its pledge to forego big-time M&A. Such deals "turn out to be nothing but expensive," The Independent says. Derek Lowe at In the Pipeline agrees, as you know; "GSK's at least not going to merge," he says. We'll see how that strategy plays out.

 - read the story in the Telegraph
- check out the FT's take
- see the article in the Independent
- find In the Pipeline's post

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.